Skip to main content
BioCryst Pharmaceuticals, Inc. (BCRX)
NASDAQ: BCRX · Real-Time Price · USD
10.02
-0.25 (-2.48%)
May 7, 2025, 10:54 AM EDT - Market open

BioCryst Pharmaceuticals Revenue by Segment
Period Ending Mar 31, 2025Dec 31, 2024Sep 30, 2024Jun 30, 2024Mar 31, 2024Dec 31, 2023Sep 30, 2023Jun 30, 2023Mar 31, 2023Dec 31, 2022
Orladeyo
483.04M 437.66M 404.36M 373.72M 346.44M 325.99M 305.84M 286.13M
Orladeyo Growth
39.43% 34.26% 32.21% 30.61% 28.15% 29.55% - -
Other
20.45M 13.05M 8.22M 8.51M 8.95M 5.42M 11.72M 20.51M
Other Growth
128.43% 140.72% -29.82% -58.49% -53.71% -71.75% - -

Revenue by Type
Period Ending Dec 31, 2024Sep 30, 2024Jun 30, 2024Mar 31, 2024Dec 31, 2023Sep 30, 2023Jun 30, 2023Mar 31, 2023Dec 31, 2022
Product
442.67M 404.06M 373.29M 345.80M 324.70M 312.02M 301.95M 286.33M
Product Growth
36.33% 29.50% 23.63% 20.77% 21.29% - - -
Collaborative and Other
8.04M 8.52M 8.95M 9.59M 6.72M 5.54M 4.70M 3.35M
Collaborative and Other Growth
19.77% 53.86% 90.65% 186.19% 115.46% - - -

Revenue by Geography
Period Ending Dec 31, 2024Sep 30, 2024Jun 30, 2024Mar 31, 2024Dec 31, 2023Sep 30, 2023Jun 30, 2023Mar 31, 2023Dec 31, 2022
US
385.96M 358.41M 330.57M 307.48M 288.36M 272.55M 257.39M 243.27M
US Growth
33.85% 31.50% 28.43% 26.39% 27.39% - - -
Outside of US
51.70M 45.94M 43.15M 38.97M 37.63M 33.29M 28.74M 27.07M
Outside of US Growth
37.39% 38.00% 50.14% 43.94% 48.88% - - -
Source: Business metrics provided by Main Street Data and sourced from official company press releases and documents.